Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 16 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

15Total
Not Applicable (1)
P 1 (2)
P 2 (12)

Trial Status

Unknown6
Recruiting5
Active Not Recruiting2
Enrolling By Invitation1
Completed1
Not Yet Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 1 completed trials

Clinical Trials (16)

Showing 16 of 16 trials
NCT07549100RecruitingPrimary

Efficacy and Safety of Tislelizumab Plus Chemotherapy as Conversion Therapy in Unresectable Locally Advanced ESCC

NCT06356688Phase 2RecruitingPrimary

A Clinical Study on the Efficacy and Safety of Paclitaxel Polymeric Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma

NCT03914443Phase 1CompletedPrimary

A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma

NCT06843889Phase 2RecruitingPrimary

A Phase II Study of Toripalimab Combined With Sequential Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma

NCT06907602Phase 2RecruitingPrimary

Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma

NCT06715501Not ApplicableEnrolling By InvitationPrimary

Efficacy and Safety of Cadonilimab and Chemoradiotherapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma

NCT05520619Phase 2Active Not Recruiting

Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002)

NCT06342167Phase 2Active Not RecruitingPrimary

Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma

NCT06426797Phase 2Not Yet RecruitingPrimary

Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

NCT06187597Phase 2RecruitingPrimary

Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)

NCT05743504Phase 1UnknownPrimary

Immunotherapy With CCRT Followed by Surgery for Locally Advanced ESCC Patients

NCT05522894Phase 2Unknown

AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC

NCT03917966Phase 2UnknownPrimary

The Phase II Trial of SHR-1210 Combined With Preoperative Chemotherapy or Apatinib for Locally Advanced ESCC

NCT05130684Phase 2UnknownPrimary

Neo-NTP-CRT for Locally Advanced ESCC

NCT04888403Phase 2UnknownPrimary

Exploring the Safety and Effectiveness of Toripalimab Combined With Neoadjuvant Radiotherapy and Chemotherapy in the Locally Advanced Esophageal Squamous Cell Carcinoma

NCT04602013Phase 2UnknownPrimary

Sintilimab Injection Combined With Concurrent CCRT in Locally Advanced Esophageal Squamous Cell Carcinoma

Showing all 16 trials

Research Network

Activity Timeline